See more : Timbercreek Financial Corp. (TBCRF) Income Statement Analysis – Financial Results
Complete financial analysis of DURECT Corporation (DRRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DURECT Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Laramide Resources Ltd. (LAM.TO) Income Statement Analysis – Financial Results
- Premier American Uranium Inc. (PUR.V) Income Statement Analysis – Financial Results
- Randstad N.V. (RANJF) Income Statement Analysis – Financial Results
- Flowsparks NV (FLSP.BR) Income Statement Analysis – Financial Results
- The Kiyo Bank, Ltd. (8370.T) Income Statement Analysis – Financial Results
DURECT Corporation (DRRX)
About DURECT Corporation
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.55M | 19.28M | 13.98M | 30.11M | 29.56M | 18.56M | 49.17M | 14.03M | 19.12M | 19.40M | 15.33M | 53.07M | 33.49M | 31.59M | 24.29M | 25.96M | 30.68M | 21.89M | 28.57M | 13.85M | 11.84M | 7.19M | 6.52M | 3.16M | 86.00K |
| Cost of Revenue | 1.72M | 1.59M | 1.96M | 1.41M | 4.14M | 4.26M | 6.63M | 5.29M | 3.91M | 5.69M | 4.84M | 4.65M | 4.71M | 4.28M | 5.34M | 3.37M | 3.23M | 3.25M | 2.82M | 2.73M | 2.43M | 3.09M | 3.40M | 1.29M | -272.00K |
| Gross Profit | 6.83M | 17.70M | 12.02M | 28.71M | 25.42M | 14.30M | 42.54M | 8.74M | 15.22M | 13.72M | 10.49M | 48.42M | 28.77M | 27.32M | 18.95M | 22.59M | 27.45M | 18.65M | 25.76M | 11.12M | 9.41M | 4.10M | 3.13M | 1.86M | 358.00K |
| Gross Profit Ratio | 79.91% | 91.76% | 86.01% | 95.33% | 85.99% | 77.04% | 86.51% | 62.28% | 79.58% | 70.69% | 68.44% | 91.23% | 85.93% | 86.47% | 78.01% | 87.04% | 89.49% | 85.16% | 90.15% | 80.30% | 79.49% | 57.05% | 47.92% | 59.08% | 416.28% |
| Research & Development | 29.35M | 36.86M | 31.85M | 27.71M | 30.21M | 25.50M | 31.61M | 29.27M | 24.32M | 22.43M | 18.95M | 20.27M | 34.05M | 36.21M | 34.91M | 39.41M | 38.34M | 37.24M | 28.90M | 24.23M | 20.95M | 29.55M | 24.57M | 13.34M | 6.36M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.42M | 13.17M | 11.83M | 11.57M | 12.28M | 12.71M | 12.10M | 13.57M | 14.94M | 15.02M | 15.46M | 13.62M | 12.42M | 11.27M | 9.95M | 8.40M | 12.17M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 116.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.36M | 15.92M | 14.45M | 13.61M | 14.36M | 12.42M | 13.17M | 11.83M | 11.57M | 12.28M | 12.71M | 12.10M | 13.57M | 14.94M | 15.14M | 15.46M | 13.62M | 12.42M | 11.27M | 9.95M | 8.40M | 12.17M | 12.08M | 9.85M | 3.04M |
| Other Expenses | 0.00 | 23.66M | 25.52M | 3.77M | 12.08M | 17.29M | 8.03M | 27.39M | 16.49M | 14.17M | 15.36M | 0.00 | 11.69M | 16.12M | 22.45M | 48.00K | 31.00K | 424.00K | 1.21M | 1.25M | 1.34M | 1.34M | 1.84M | 1.50M | 311.00K |
| Operating Expenses | 43.72M | 52.78M | 46.30M | 41.32M | 44.57M | 37.92M | 44.77M | 41.10M | 35.88M | 34.71M | 31.65M | 32.36M | 47.63M | 51.15M | 50.05M | 68.40M | 51.99M | 50.08M | 41.38M | 35.43M | 30.69M | 43.07M | 38.50M | 24.69M | 9.72M |
| Cost & Expenses | 45.43M | 54.37M | 48.25M | 42.73M | 48.72M | 42.18M | 51.41M | 46.39M | 39.79M | 40.40M | 36.49M | 37.01M | 52.34M | 55.43M | 55.39M | 71.77M | 55.22M | 53.33M | 44.20M | 38.16M | 33.11M | 46.15M | 41.90M | 25.98M | 9.45M |
| Interest Income | 2.13M | 2.15M | 156.00K | 517.00K | 1.07M | 870.00K | 967.00K | 143.00K | 237.00K | 39.00K | 0.00 | 151.00K | 134.00K | 943.00K | 420.00K | 1.55M | 0.00 | 3.83M | 2.27M | 0.00 | 1.04M | 0.00 | 0.00 | 3.10M | 0.00 |
| Interest Expense | 2.79M | 2.40M | 2.15M | 2.24M | 2.50M | 2.57M | 2.43M | 2.29M | 2.24M | 1.15M | 290.00K | 7.00K | 46.00K | 6.00K | 36.00K | 789.00K | 2.63M | 3.44M | 4.36M | 0.00 | 2.46M | 0.00 | 0.00 | 131.00K | 0.00 |
| Depreciation & Amortization | 148.00K | 150.00K | 132.00K | 297.00K | 291.00K | 254.00K | 437.00K | 416.00K | 425.00K | 601.00K | 558.00K | 964.00K | 1.18M | 2.25M | 2.51M | 48.00K | 2.32M | 2.46M | 3.17M | 4.64M | 4.75M | 4.32M | 3.30M | 1.50M | 311.00K |
| EBITDA | -24.68M | -32.78M | -33.99M | -11.80M | -18.58M | -22.50M | -833.00K | -31.81M | -20.00M | -20.36M | -20.60M | 17.16M | -17.59M | -20.64M | -27.75M | -45.76M | -22.22M | -28.97M | -12.46M | -18.43M | -16.53M | -34.65M | -32.07M | -21.32M | -9.05M |
| EBITDA Ratio | -288.77% | -170.79% | -244.09% | -40.18% | -61.15% | -122.54% | -2.58% | -229.74% | -106.81% | -108.03% | -138.08% | 32.36% | -56.30% | -75.45% | -129.75% | -176.30% | -70.11% | -121.89% | -42.20% | -141.98% | -139.70% | -482.25% | -276.58% | -675.85% | -10,520.93% |
| Operating Income | -36.88M | -35.08M | -34.27M | -12.62M | -19.15M | -23.62M | -2.24M | -32.36M | -20.66M | -21.00M | -21.16M | 16.06M | -18.85M | -23.84M | -31.10M | -45.81M | -24.54M | -31.44M | -15.63M | -24.31M | -21.28M | -38.97M | -49.40M | -22.82M | -9.36M |
| Operating Income Ratio | -431.49% | -181.93% | -245.21% | -41.89% | -64.78% | -127.23% | -4.55% | -230.76% | -108.05% | -108.23% | -138.08% | 30.25% | -56.30% | -75.45% | -128.02% | -176.48% | -80.00% | -143.58% | -54.70% | -175.48% | -179.80% | -542.37% | -757.23% | -723.39% | -10,882.56% |
| Total Other Income/Expenses | 9.26M | -251.00K | -1.99M | -1.72M | -1.43M | -1.70M | -1.46M | -2.15M | -2.00M | -1.11M | -290.00K | 144.00K | 88.00K | 937.00K | 811.00K | 758.00K | 202.00K | -1.89M | -2.50M | -3.31M | -1.42M | 1.80M | 4.47M | 0.00 | 0.00 |
| Income Before Tax | -27.62M | -35.33M | -36.27M | -14.34M | -20.58M | -25.32M | -3.70M | -34.51M | -22.66M | -22.11M | -21.45M | 16.20M | -18.77M | -22.90M | -30.29M | -43.91M | -24.34M | -33.33M | -18.12M | -27.62M | -22.70M | -37.17M | -44.93M | 0.00 | 0.00 |
| Income Before Tax Ratio | -323.16% | -183.23% | -259.46% | -47.61% | -69.60% | -136.40% | -7.51% | -246.05% | -118.51% | -113.96% | -139.97% | 30.53% | -56.04% | -72.48% | -124.68% | -169.15% | -79.34% | -152.22% | -63.43% | -199.37% | -191.79% | -517.37% | -688.66% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 251.00K | 1.86M | -11.81M | 2.21M | 870.00K | 530.00K | -273.00K | -188.00K | -562.00K | -558.00K | 151.00K | -1.18M | -2.25M | -2.89M | -12.69M | -202.00K | 1.89M | 4.00K | 18.00K | 0.00 | 0.00 | 9.56M | -2.97M | -651.00K |
| Net Income | -27.62M | -35.58M | -38.13M | -2.52M | -22.79M | -25.32M | -3.70M | -34.51M | -22.66M | -22.11M | -21.45M | 16.20M | -18.77M | -22.90M | -30.72M | -45.05M | -24.34M | -33.33M | -18.13M | -27.64M | -22.70M | -37.17M | -44.93M | -19.85M | -8.71M |
| Net Income Ratio | -323.16% | -184.54% | -272.77% | -8.38% | -77.08% | -136.40% | -7.51% | -246.05% | -118.51% | -113.96% | -139.97% | 30.53% | -56.04% | -72.48% | -126.44% | -173.56% | -79.34% | -152.22% | -63.45% | -199.50% | -191.79% | -517.37% | -688.66% | -629.19% | -10,125.58% |
| EPS | -1.22 | -1.56 | -1.69 | -0.13 | -1.28 | -1.60 | -0.25 | -2.60 | -1.91 | -2.00 | -2.10 | 1.80 | -2.15 | -2.64 | -3.68 | -5.75 | -3.45 | -5.05 | -3.37 | -5.37 | -4.49 | -7.69 | -9.68 | -11.60 | -3.66 |
| EPS Diluted | -1.20 | -1.56 | -1.69 | -0.13 | -1.28 | -1.58 | -0.25 | -2.59 | -1.91 | -1.98 | -2.08 | 1.80 | -2.15 | -2.64 | -3.68 | -5.75 | -3.45 | -5.05 | -3.37 | -5.37 | -4.49 | -7.69 | -9.68 | -6.01 | -3.66 |
| Weighted Avg Shares Out | 26.26M | 22.78M | 22.50M | 19.95M | 17.80M | 15.84M | 14.53M | 13.27M | 11.85M | 11.06M | 10.22M | 8.84M | 8.74M | 8.69M | 8.34M | 7.83M | 7.05M | 6.60M | 5.37M | 5.15M | 5.05M | 4.83M | 4.64M | 1.71M | 2.38M |
| Weighted Avg Shares Out (Dil) | 26.52M | 22.78M | 22.50M | 19.95M | 17.80M | 15.98M | 14.53M | 13.32M | 11.85M | 11.17M | 10.31M | 8.86M | 8.74M | 8.69M | 8.34M | 7.83M | 7.05M | 6.60M | 5.37M | 5.15M | 5.05M | 4.83M | 4.64M | 3.31M | 2.38M |
DURECT Corporation (DRRX) CEO Jim Brown on Q3 2020 Results - Earnings Call Transcript
DURECT Corporation (DRRX) CEO Jim Brown on Q3 2020 Results - Earnings Call Transcript
Durect (DRRX) Reports Q3 Loss, Lags Revenue Estimates
Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -23.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
DURECT Co. (NASDAQ:DRRX) Expected to Post Quarterly Sales of $4.03 Million
Brokerages expect DURECT Co. (NASDAQ:DRRX) to post $4.03 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for DURECT’s earnings, with the highest sales estimate coming in at $4.60 million and...
Durect (DRRX) Investor Presentation - Slideshow
The following slide deck was published by DURECT Corporation in conjunction with this event.
IPO Update: PainReform Readies U.S. IPO Plan (Pending:PRFX)
PainReform has filed to raise $23 million in a U.S. IPO.
Durect Corp (DRRX) Q2 2020 Earnings Call Transcript | The Motley Fool
DRRX earnings call for the period ending June 30, 2020.
Jane Street Group LLC Invests $379,000 in DURECT Co. (NASDAQ:DRRX)
Jane Street Group LLC purchased a new position in shares of DURECT Co. (NASDAQ:DRRX) in the 1st quarter, HoldingsChannel.com reports. The institutional investor purchased 244,867 shares of the specialty pharmaceutical company’s stock, valued at approximately $379,000. A number of other...
DURECT (NASDAQ:DRRX) Receives Buy Rating from B. Riley
B. Riley restated their buy rating on shares of DURECT (NASDAQ:DRRX) in a research note issued to investors on Monday morning, TipRanks reports. B. Riley currently has a $5.00 price objective on the specialty pharmaceutical company’s stock. DRRX has been...
-$0.04 Earnings Per Share Expected for DURECT Co. (NASDAQ:DRRX) This Quarter
Equities research analysts expect that DURECT Co. (NASDAQ:DRRX) will post earnings per share of ($0.04) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for DURECT’s earnings, with the lowest EPS estimate coming in at ($0.05) and...
Source: https://incomestatements.info
Category: Stock Reports